Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Newsummit Acquires Novel HCV Treatment from UK's MRC Technology

publication date: Mar 14, 2017
Shanghai Newsummit Biopharma in-licensed rights to a novel antibody targeting Hepatitis C virus from MRC Technology of the UK. Newsummit, a CRO with expertise in process development and clinical studies, is a unit of Zhejiang Yatai Pharma, an infectious disease company. Newsummit has established a collaborative CRO network for other services. MRC said the novel molecule was humanized by MRC Tech scientists, and originated in the laboratory of Prof. Arvind Patel, of the MRC-University of Glasgow Centre for Virus Research. Financial details were not disclosed. More details....

Stock Symbol: (SHZ: 002370)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital